(Bloomberg) -- Syngenta AG, in the process of being taken over by China National Chemical Corp. for $43 billion, withheld paying a dividend as it expects the deal to close in the second quarter of this year.
While ChemChina is in the final stages of its acquisition, obtaining the necessary regulatory approvals from antitrust authorities has turned out to be among the more lengthy and complex of stages. The conclusion of a review in Europe has been delayed until mid-April while authorities digest a suggested remedy package. ChemChina said Jan. 20 it filed for antitrust approval in the U.S.
In what is likely to be Syngenta’s final annual earnings report as a listed company, earnings per share declined 4 percent to $17.03, while revenue slipped 5 percent to $12.79 billion. Analysts in a Bloomberg survey predicted $16.4 per share, from $12.9 billion in sales.
(Corrects second paragraph to show ChemChina filed for approval in U.S.)
To contact the reporter on this story: Andrew Noël in London at firstname.lastname@example.org. To contact the editors responsible for this story: Tara Patel at email@example.com, Phil Serafino
©2017 Bloomberg L.P.